FAMEDs Newsletter #1
May 5, 2011

Thank you for requesting an update on our actions to save the 17,500 Avastin women. If each of you that signed the petition can get just one more person to sign, we will by definition double the # of petition signers.

Late on Monday, 25th April FAMEDS filed a Freedom of Information Act request of the FDA with some of its supporters in this battle. We did so not because we wanted to but because we were not pleased with the actions of the FDA and felt that the only way to get at the truth was to compel the Agency to be forthcoming with information. Some of the publications covering the press release are listed below.

This being America, we are blessed with the First Amendment: “Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the Government for a redress of grievances.”

We shall hold a protest outside the FDA headquarters in Silver Spring, Maryland on June 28th, probably from 7 a.m. to 9 a.m. For those interested in attending, the sign-up sheet shall go live on our website at www.fameds.org in the next 48 hours. We shall hold an organizing meeting for the protest at 8 pm EST on Thursday, May 5th and it will run a maximum of 30 minutes. For those that wish to participate, here are the call-in details:

Conference Dial-in Number: (605) 475-4000
Participant Access Code: 586521#

The following was an article that was published April 26th, 2011 followed by the FAMEDS response. Apologies for one error – capecitabine is of course Xeloda as our good friend, Dr. David Nathanson, pointed out to an embarrassed Terry Kalley.
We also received favorable coverage in this article:
Below are some of the publications that covered our Freedom of Information Act press release:
Avastin Fight Song

Composer and performer, Andrew Katz, NYC

Latest News
Cancer drug's approval matter of life, death
Read More
Local couple fighting FDA over cancer drug Avastin
Read More